Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24784545 | 1.00 | NPBWR1 (0.41) | NPBWR1KDM4EPTPN1CCR2MEN1 | |
| SCHEMBL24784564 | 0.91 | NPBWR1 (0.41) | NPBWR1KDM4EMEN1KMT2AGCGR | |
| SCHEMBL30103029 | 0.91 | NPBWR1 (0.41) | NPBWR1KDM4EMEN1KMT2AGCGR | |
| SCHEMBL30103052 | 0.90 | KMT2A (0.47) | CCR2KMT2AEGLN1 | |
| SCHEMBL24785096 | 0.90 | KMT2A (0.47) | CCR2KMT2AEGLN1 | |
| SCHEMBL24785451 | 0.88 | MEN1 (0.43) | KDM4EMEN1KMT2ASMN1; SMN2EGLN1 | |
| SCHEMBL30018739 | 0.88 | MEN1 (0.43) | KDM4EMEN1KMT2ASMN1; SMN2EGLN1 | |
| SCHEMBL24785076 | 0.87 | ALKBH1 (0.41) | KDM4EMEN1KMT2A | |
| SCHEMBL30103094 | 0.87 | ALKBH1 (0.41) | KDM4EMEN1KMT2A | |
| SCHEMBL24784619 | 0.87 | P2RX7 (0.38) | KDM4EPTPN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115448913-A | Bicyclic compounds for the treatment of EP2, EP4 receptor mediated diseases | 武汉人福创新药物研发中心有限公司 | 2022-12-09 | — | — | CN | disclosed |